Discontinued — last reported Q4 '25
Baker Hughes Interest Paid decreased by 42.3% to $56.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 12.0%, from $50.00M to $56.00M. Over 3 years (FY 2022 to FY 2025), Interest Paid shows relatively stable performance with a 0.3% CAGR. This is a positive signal — lower values indicate better performance for this metric.
An increase in interest paid relative to debt levels may signal rising borrowing costs or higher leverage, while a decrease may indicate debt reduction or refinancing at lower rates.
The total cash outflow for interest payments on debt obligations, typically disclosed as a supplemental item in the cash...
Essential for comparing the cost of capital and debt burden across peers in the pharmaceutical industry.
cf_interest_paid| Q2 '21 | Q3 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $106.00M | $47.00M | $48.00M | $92.00M | $50.00M | $101.00M | $50.00M | $107.00M | $48.00M | $104.00M | $48.00M | $102.00M | $49.00M | $99.00M | $50.00M | $98.00M | $49.00M | $97.00M | $56.00M |
| QoQ Change | — | -55.7% | +2.1% | +91.7% | -45.7% | +102.0% | -50.5% | +114.0% | -55.1% | +116.7% | -53.8% | +112.5% | -52.0% | +102.0% | -49.5% | +96.0% | -50.0% | +98.0% | -42.3% |
| YoY Change | — | — | — | -13.2% | +6.4% | — | +4.2% | +16.3% | -4.0% | +3.0% | -4.0% | -4.7% | +2.1% | -4.8% | +4.2% | -3.9% | +0.0% | -2.0% | +12.0% |